Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869746 | 0.70 | — | — | |
| SCHEMBL9716940 | 0.68 | — | — | |
| SCHEMBL10768329 | 0.67 | — | — | |
| SCHEMBL14742396 | 0.60 | — | — | |
| SCHEMBL560767 | 0.59 | — | — | |
| SCHEMBL28758944 | 0.59 | PTGS2 (0.51) | TDP1 | |
| SCHEMBL360448 | 0.59 | ACMSD (0.47) | TDP1 | |
| SCHEMBL15973332 | 0.58 | — | — | |
| SCHEMBL2988908 | 0.58 | GRM2 (0.31) | TDP1 | |
| SCHEMBL30767406 | 0.57 | CHRNB4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134517-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134516-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024025260-A1 | FLUORESCENT PROBE COMPOUND AND COMPOSITE COMPRISING SAME | 한국생명공학연구원 | 2024-02-01 | — | — | WO | disclosed |
| WO-2022235077-A1 | NOVEL SIDEROPHORE COMPOUND AND METAL NANOPARTICLE COMPLEX USING SAME | 한국생명공학연구원 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022211314-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | 엘티소재주식회사 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022186645-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | 엘티소재주식회사 | 2022-09-09 | — | — | WO | disclosed |
| US-11302873-B2 | Organic light-emitting device | LT MATERIALS CO, LTD. (KR) | 2022-04-12 | — | — | US | disclosed |
| EP-0751129-B3 | Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them | BIAL PORTELA & CA SA (PT) | 2020-05-13 | — | — | EP | disclosed |
| US-20120022047-A1 | PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE | GLENMARK GENERICS LTD (IN) | 2012-01-26 | — | — | US | disclosed |
| US-7863443-B2 | Phosphoramidite ligand and production method of allylic amine using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20090054689-A1 | PHOSPHORAMIDITE LIGAND AND PRODUCTION METHOD OF ALLYLIC AMINE USING THE SAME | Carreira, Erick M. (CH) | 2009-02-26 | — | — | US | disclosed |
| US-20060142566-A1 | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide and new crystal forms thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1551808-A1 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ b,f AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551808-A1 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ b,f AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1414806-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| WO-2004031155-A1 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031155-A1 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003011834-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
| EP-0751129-B1 | Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them | PORTELA & CA SA (PT) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054689-A1 | PHOSPHORAMIDITE LIGAND AND PRODUCTION METHOD OF ALLYLIC AMINE USING THE SAME | ADH5, SELENOI, ADH1A | CYP1A2 1817/4885GRM5 395/4885TDP1 4379/4885 |
| US-20120022047-A1 | PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE | CACNA1A, GABRE, CACNA1D | CYP1A2 309/4885GRM5 425/4885TDP1 4490/4885 |
| US-20060142566-A1 | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide and new crystal forms thereof | HRH4, HRH1, HRH3 | CYP1A2 11/4885GRM5 922/4885TDP1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.